bioAffinity Technologies, Inc. (NASDAQ:BIAF), currently trading at $0.23 and down nearly 88% over the past year, has been granted a patent by the China National Intellectual Property Administration for its composition and method targeting CD320 and LRP2 receptors to selectively kill cancer cells, the company announced Tuesday.
The patent, titled "Compositions and Methods for Treating Cancer," covers small interfering RNAs (siRNAs) and their use in cancer treatment. This adds to the company’s intellectual property portfolio, which includes U.S. Patent No. 12,305,171 for the same technology. With a market capitalization of just $6.34 million, bioAffinity is actively developing its portfolio despite challenging financial metrics.
According to the company’s press release statement, laboratory research demonstrates that the siRNA-driven suppression of CD320 and LRP2 proteins effectively targets cancer cells from multiple tumor types including lung, breast, prostate, brain, and skin without affecting normal cells.
bioAffinity is exploring applications of this technology as a topical treatment for skin cancers and lesions. This development complements the company’s diagnostic platform, CyPath® Lung, a non-invasive test for early-stage lung cancer detection.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.